Compare GTE & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GTE | MDWD |
|---|---|---|
| Founded | 2003 | 2000 |
| Country | Canada | Israel |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medicinal Chemicals and Botanical Products |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 209.3M | 193.3M |
| IPO Year | 2007 | 2013 |
| Metric | GTE | MDWD |
|---|---|---|
| Price | $8.06 | $17.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $36.00 |
| AVG Volume (30 Days) | ★ 680.0K | 101.2K |
| Earning Date | 05-01-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $374,460,000.00 | N/A |
| Revenue This Year | $1.39 | $48.88 |
| Revenue Next Year | $2.84 | $35.08 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 41.99 | N/A |
| 52 Week Low | $3.09 | $14.90 |
| 52 Week High | $9.74 | $22.51 |
| Indicator | GTE | MDWD |
|---|---|---|
| Relative Strength Index (RSI) | 51.73 | 50.90 |
| Support Level | $3.75 | $16.77 |
| Resistance Level | $9.74 | $18.71 |
| Average True Range (ATR) | 0.49 | 0.88 |
| MACD | -0.15 | 0.12 |
| Stochastic Oscillator | 30.21 | 69.04 |
Gran Tierra Energy Inc is an independent energy company. The company, along with its subsidiaries, is focused on oil and gas exploration and production, with assets in Colombia, Canada, and Ecuador. It produces oil, natural gas, and natural gas liquids. Gran Tierra has assembled a diversified, high-quality asset base that is fully operated in Colombia and Ecuador and partly in Canada. The company operates various blocks in Colombia and Ecuador, spanning three basins. It also has contiguous areas in Alberta, Canada, spanning various gross acres across the Western Canadian Sedimentary Basin. The company's reportable segments are Colombia, Ecuador, Canada, and Other. A majority of its revenue is derived from its operations in Colombia.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.